{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '17', 'Version Date: 07/22/2019', 'PHEO/PGL: Patients with recurrent or progressive disease will be eligible. Newly', 'diagnosed patients with PHEO/PGL that is metastatic at diagnosis and/or unresectable', 'will be eligible Patients with PHEO/PGL with localized (non-metastatic), resectable', 'disease will not be eligible.', 'Renal cell cancer associated with HLRCC: Patients with localized, resectable', 'HLRCC-associated renal cell cancer will not be eligible. Patients with metastatic', 'and/or unresectable HLRCC-associated renal cell cancer will be eligible.', '3.1.1.2 Have one of the following confirmed histologically, cytologically, or through', 'biochemical testing:', 'wild-type GIST (GIST without KIT or PDGFRA mutation);', 'PHEO/PGL with a germline mutation in SDHA, SDHB, SDHC, or SDHD;', 'renal cell cancer associated with HLRCC.', 'Testing will be performed in CLIA certified labs using genetic tests for KIT/PDGFRA', 'and testing panels developed for patients with PHEO/PGL. Results from outside labs will', 'be accepted. Pathologic diagnosis will be reviewed and verified at the Clinical Center.', '3.1.1.3 Age: be > 12 years of age', 'Because there is no dosing or adverse event data currently available on the use of SGI-110 in', 'children < 18 year of age, children < 12 years of age will be excluded from this study, but', 'may be eligible for future pediatric trials should the results of the study be positive.', '3.1.1.4 Measurable disease:', 'Have measurable disease, defined as at least one lesion that can be accurately measured in at', 'least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for', 'nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.', 'See Section 8.2.2 for the evaluation of measurable disease (RECIST v1.1).', '3.1.1.5 Prior Therapy', '3.1.1.5. 1 Prior therapy requirements:', 'Wt-GIST: Because there are no standard chemotherapy regimens known to be', 'effective for wt-GIST, previously untreated participants are eligible.', 'PHEO/PGL with germline SDH subunit mutation: 131I-MIBG in patients with MIBG', 'avid tumors or cytotoxic chemotherapy (CVD or temozolomide) is required prior to', 'enrollment on this trial. However, patients who have refused cytotoxic chemotherapy', 'or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is', 'felt to be in the best interest for the patient by the local investigator will also be', 'eligible.', 'HLRCC-associated renal cell cancer: Because there are no standard chemotherapy', 'regimens known to be effective for HLRCC-associated renal cell cancer, previously', 'untreated participants are eligible.', '3.1.1.5.2Prior therapy wash-out period requirements', 'Participants must be at least 4 weeks from prior surgical procedures and surgical', 'incisions must be healed.']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '18', 'Version Date: 07/22/2019', 'Participants must have had their last fraction of external beam radiation therapy at', 'least 4 weeks prior to enrollment. Participants with prior radiation therapy must be at', 'least 4 weeks post therapy and have had progression of disease outside the radiation', 'port.', 'Participants must have had their last dose of cytotoxic chemotherapy at least 28 days', 'prior to enrollment, their last dose of biological therapy, such as biological response', 'modifiers (e.g., cytokines), immunomodulatory agents, vaccines, differentiating', 'agents, used to treat their cancer at least 28 days prior to enrollment, their last dose of', 'a monoclonal antibody at least 28 days prior to enrollment, and their last dose of any', 'investigational agent at least 28 days prior to enrollment.', 'Participants must have recovered from the acute toxic effects of prior therapy to a', 'grade 1 (CTCAE v.5.0) level prior to enrollment (does not apply to alopecia).', '3.1.1.6 Performance Level: ECOG performance status <2 or Karnofsky >60% in patients', '>', '16 years of age, Lansky > 60 for patients VI 16 years of age (See Appendix I).', '3.1.1.7 Have normal organ and marrow function as defined below:', '- absolute neutrophil count', '>1,500/mcL', '- platelets', '>100,000/mcL', '- total bilirubin', 'within normal institutional limits', '- AST(SGOT)/ALT(SGPT)', '<2.5 X institutional upper limit of', 'normal', '- creatinine', 'within normal institutional limits', 'OR', '- creatinine clearance', '>60 mL/min/1.73 m\u00b2 for patients with', 'creatinine levels above institutional', 'normal.', '3.1.1.8 Birth Control:', 'The effects of SGI-110 on the developing human fetus are unknown. For this reason and', 'because decitabine is known to be teratogenic, women of child-bearing potential and men must', 'agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)', 'prior to study entry and for the duration of study participation, and for 6 months following', 'participation. Should a woman become pregnant or suspect she is pregnant while she or her', 'partner is participating in this study, she should inform her treating physician immediately.', '3.1.1.9 Ability of subject or legal guardians (if the patient is <18 years old) to understand', 'and the willingness to sign a written informed consent document.', '3.1.2 Exclusion Criteria', 'Patients with any one the following will be excluded:', '3.1.2.1 Ongoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor,', 'immunotherapy, or biologic therapy, including investigational agents for their', 'disease.', '3.1.2.2 History of allergic reactions to SGI-110 or decitabine.', '3.1.2.3', 'Uncontrolled intercurrent illness including, but not limited to, symptomatic', 'congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic']\n\n###\n\n", "completion": "END"}